Related Experiment Video
Updated: Aug 10, 2026

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
Colonoscopic or Capsule Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection: A
Dina Belhasan1, Nataliia Kuchma2, Monika Fischer3
1Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
Background And Aims:
Fecal microbiota transplant (FMT) is effective for preventing recurrent Clostridioides difficile infection (rCDI). Prior studies suggest that capsule and colonoscopic FMT administration are similarly effective, although the studies may be limited by small sample size or selection bias. The aim of this study was to compare the CDI recurrent rates following capsule or colonoscopic FMT.
Methods:
Prospective cohort of patients with rCDI treated with capsule or colonoscopic FMT between 7/1/19 and 11/29/23. This study's primary outcome was 1-month CDI recurrence rates. Predictors of recurrence were assessed using multivariate logistic regression.
Results:
Overall, 652 individuals received FMT (421 capsule, 223 colonoscopy). Those receiving capsule FMT were older (median 70 vs 59 years, P < .001). At 1 month, CDI recurrence was higher with capsule compared to colonoscopic FMT (18% vs 7.4%, P = .001). On multivariate analysis, capsule FMT was associated with increased rCDI risk (adjusted odds ratio [OR]: 2.37, 95% confidence interval [CI]: 1.16-5.24, P = .023). Stratified analyses by age showed capsule FMT increased recurrence risk only in patients ≥65 years (OR: 2.7, 95% CI: 1.2-6.4), but not in those <65 years (OR: 2.7, 95% CI: 1.2-6.4). Beyond 1-month, non-CDI antibiotic exposure became the predominant predictor of recurrence.
Conclusion:
FMT by capsule may be associated with higher CDI recurrence compared to FMT by colonoscopy. This effect appears be greater in individuals older than 65 years, thus highlighting the importance of individualized treatment decisions that balance FMT efficacy with procedural risks. Development of microbiota-based therapeutics for CDI should account for the impact of administration route on efficacy.
Insights
Fecal microbiota transplant (FMT) via capsule may lead to higher recurrent Clostridioides difficile infection (rCDI) rates than colonoscopic FMT, especially in older adults. This highlights the need for individualized treatment decisions in CDI prevention.
Area of Science:
- Gastroenterology
- Infectious Diseases
- Microbiome Research
Background:
- Fecal microbiota transplant (FMT) is a proven treatment for recurrent Clostridioides difficile infection (rCDI).
- Previous research suggests comparable efficacy between capsule and colonoscopic FMT, but with limitations in sample size and potential selection bias.
- The optimal administration route for FMT in rCDI remains an area of investigation.
Purpose of the Study:
- To compare the rates of CDI recurrence after FMT administration via capsules versus colonoscopy.
- To identify predictors of CDI recurrence following different FMT administration routes.
- To evaluate the impact of patient age on the efficacy of capsule versus colonoscopic FMT.
Main Methods:
- A prospective cohort study included 652 patients with rCDI treated with either capsule (n=421) or colonoscopic (n=223) FMT.
- The primary outcome was the 1-month CDI recurrence rate.
- Multivariate logistic regression was used to assess predictors of recurrence, with stratified analyses by age.
Main Results:
- Capsule FMT recipients were older (median 70 vs 59 years).
- One-month CDI recurrence was significantly higher with capsule FMT (18%) compared to colonoscopic FMT (7.4%) (P=.001).
- Capsule FMT was independently associated with increased rCDI risk (aOR: 2.37), particularly in patients aged 65 years and older.
Conclusions:
- FMT administered via capsules may be associated with a higher risk of CDI recurrence than FMT via colonoscopy.
- This increased risk appears more pronounced in patients aged 65 years and older.
- Administration route is a critical factor influencing FMT efficacy for CDI, necessitating personalized treatment strategies.
Related Concept Videos
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Drugs for Treatment of Constipation-Predominant IBS
Microbiota of the Large Intestine
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Microbiota Modulation by Antibiotics
Dysbiosis of the Gut Microbiota
